The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review

Chen, Shouzhen; Zhu, Yao; Cui, Jianfeng; Wang, Yong; Xia, Yangyang; Song, Jing; Cheng, Shanshan; Zhou, Chuanen; Zhang, Dongqing; Zhang, Bing; Shi, Benkang

doi:10.1016/j.urolonc.2017.03.027

Cited by 8 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study, patients ( n = 81) had chromophobe RCC [ 35 ]. Two small studies had patients ( n = 96) only with papillary RCC (pRCC) [ 30 , 33 ] and other three had patients ( n = 752) only with clear cell RCC (ccRCC) [ 36 , 38 , 39 ]. Almost all patients had received renal surgery as primary treatment for RCC.…”

Section: Resultsmentioning

confidence: 99%

“…The criteria were briefly summarized in the Table 1 . The rates of high c-Met expression were various, ranging from 16.7% [ 29 , 36 ] to 80% [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

“…From six studies [ 28 – 31 , 35 , 36 ], 496 patients were included in the meta-analysis of odds ratios (ORs) with 95% confidence intervals (CIs) for nuclear grade and/or depth of cancer penetration (pT stage).…”

Section: Resultsmentioning

confidence: 99%

“…In RCC, many studies have suggested that c-Met expression is associated with significantly inferior clinicopathological features, such as tumor grade [ 27 , 28 – 31 , 36 , 38 ], primary tumor stage [ 30 , 31 , 36 ], lymphatic invasion [ 27 ], metastases [ 30 , 35 , 38 ], and worse progression-free survival [ 37 ] or OS [ 31 , 34 , 36 ]. However, the pathological or clinical impacts of c-Met expression are not consistent across the studies [ 33 , 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…Chen at al. had also performed the similar meta-analysis regarding clinicopatholigical impacts of c-Met expression in RCC [ 36 ]. They included studies with no criteria or low threshold for c-Met expression.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

Kim

2017

Oncotarget

View full text Add to dashboard Cite

c-Met overexpression has been observed in renal cell carcinoma (RCC). However, its clinicopathological impacts remain uncertain. We performed this meta-analysis to evaluate the pathologic and prognostic impacts of high c-Met expression in patients with RCC. A systematic computerized search of the electronic databases PubMed and Embase was performed. From 12 studies, 1,724 patients with RCC were included in the meta-analysis. Compared with RCCs showing low c-Met expression, tumors with high c-Met expression showed significantly higher nuclear grade (odds ratio = 2.45 [95% CI: 1.43–4.19], P = 0.001) and pT stage (odds ratio = 2.18 [95% CI: 1.27–3.72], P = 0.005). In addition, patients with c-Met-high RCC showed significantly worse overall survival than those with c-Met-low tumor (hazard ratio = 1.32 [95% CI: 1.12–1.56], P = 0.0009). In conclusion, this meta-analysis demonstrates that high c-Met expression correlate with significantly worse pathological features and overall survival, indicating c-Met overexpression is a potential adverse prognostic marker for patients with RCC.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The criteria were briefly summarized in the Table 1 . The rates of high c-Met expression were various, ranging from 16.7% [ 29 , 36 ] to 80% [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

Kim

2017

Oncotarget

View full text Add to dashboard Cite

show abstract

CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression

Chen

Wang

Chen

et al. 2021

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

ORP5 promotes tumor metastasis via stabilizing c-Met in renal cell carcinoma

Zhang

Zhou

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

ORP5, a lipid transporter, has been reported to increase the metastasis of several cancers. However, the potential mechanisms of ORP5 in renal cell carcinoma (RCC) remain unclear. In this study, we demonstrated that ORP5 was commonly overexpressed in tumor cells and tissues of RCC, and associated with tumor progression. Overexpression of ORP5 could promote RCC cells migration and invasion. In addition, the results suggested that the expression of ORP5 was favorably associated with c-Met expression, and ORP5 promoted RCC cells metastasis by upregulating c-Met in vitro and in vivo. Mechanistically, ORP5 facilitated the ubiquitination and degradation of c-Cbl (the E3 ligase of c-Met), and thus inhibited c-Met lysosomal degradation, which resulted in the stabilization of c-Met. In general, these findings revealed the role of ORP5 in contributing to tumorigenesis via upregulating c-Met in RCC.

show abstract

The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review

Cited by 8 publications

References 43 publications

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression

ORP5 promotes tumor metastasis via stabilizing c-Met in renal cell carcinoma

Contact Info

Product

Resources

About